Hemogenyx Pharmaceuticals annual debt-to-assets ratio
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Debt-to-Assets Ratio Growth & History (HEMO)
Hemogenyx Pharmaceuticals's debt-to-assets ratio was 0.48 for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.48 | −0.14 | −22.94% |
| 2024 | 2024-12-31 | 0.62 | 0.14 | +29.09% |
| 2023 | 2023-12-31 | 0.48 | −0.00 | −0.03% |
| 2022 | 2022-12-31 | 0.48 | 0.48 | +40403.15% |
| 2021 | 2021-12-31 | 0.00 | −0.61 | −99.81% |
| 2020 | 2020-12-31 | 0.61 | — | — |
Hemogenyx Pharmaceuticals quarterly debt-to-assets ratio
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.48 | −0.14 | −22.94% |
| Q2 2025 | 2025-06-30 | 0.71 | — | — |
| Q4 2024 | 2024-12-31 | 0.62 | — | — |
Hemogenyx Pharmaceuticals debt-to-assets ratio trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's debt-to-assets ratio decreased from 0.61 to 0.48, a change of −0.13. The latest reported quarter, Q4 2025, shows 0.48.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗Community posts
Hemogenyx loss widens on non-cash options charge despite lower underlying spending
Hemogenyx Pharmaceuticals ($HEMO) reported a first-half pretax loss of £6.56 million, widening from £5.01 million. Reported operating costs increased to £6.48 million, but the company attributed most of the rise to a £5.54 million non-cash ...
